Manuel Marina Breysse, MD, MSc, José María Lillo Castellano, PhD, Carlos Lizcano de Amoroto, MSc, and Beatriz Sanau Hornero, MSc | IDOVEN
Competition Sponsor: EIT Health
Awardee Year: 2020
Cardiovascular diseases (CVDs) are the leading cause of death globally. The WHO estimates 17.9 million fatal CVDs in 2016, representing 31% of global deaths. Their associated costs will rise to €932B worldwide in 2030. Diagnostic performance and early CVDs detection can be dramatically improved with the use of electrocardiogram (ECG) reports, but today’s ECG technology is time-consuming for doctors, costly for health systems, and can barely handle current number of patients with high standards of medical practice. Most solutions today are irrelevant as they continue to focus on deploying better dashboards, thinner hardware with longer periods of records, etc., rather than solving the diagnosis issue, the true bottleneck in the ECG workflow.
The next big breakthrough in ECG technology has to be a change on how CVDs are diagnosed. WILLEM is IDOVEN’s ground-breaking, user-centric, 100% automated medical software for arrhythmia identification and CVDs prediction, built on our proprietary Artificial Intelligence. It transforms raw ECG signals from any monitoring device into a cardiologist-level ECG report.
IDOVEN 2025 social impact will be +400,000 early diagnosed CVDs, +18,000 avoided cardiac deaths, and healthcare costs reduced by +€9,000M.
To learn more about this proposal, email healthylongevity@nas.edu.